

6/5/1

DIALOG(R) File 351:Derwent WPI  
(c) 2004 Thomson Derwent. All rts. reserv.

008735741

WPI Acc No: 1991-239757/ 199133

XRAM Acc No: C91-104187

**Use of L-arginine - to treat high vascular resistance disorders e.g.  
hypertension and bronchial asthma**

Patent Assignee: LEVERE R D (LEVE-I)

Inventor: ABRAHAM N G; LEVERE R D; MARTASEK P; SCHWARTZMA M L; SCHWARTZMAN  
M L

Number of Countries: 015 Number of Patents: 004

Patent Family:

Patent No	Kind	Date	Applicat No	Kind	Date	Week
EP 441119	A	19910814	EP 91100168	A	19910107	199133 B
CA 2033766	A	19910710				199138
US 5217997	A	19930608	US 90462638	A	19900109	199324
			US 90513895	A	19900424	
			US 92873892	A	19920424	
EP 441119	A3	19921014	EP 91100168	A	19910107	199340

Priority Applications (No Type Date): US 90513895 A 19900424; US 90462638 A  
19900109; US 92873892 A 19920424

Cited Patents: NoSR.Pub; 9.Jnl.Ref; FR 2507892; WO 8500517

Patent Details:

Patent No	Kind	Lan	Pg	Main IPC	Filing Notes
-----------	------	-----	----	----------	--------------

EP 441119	A				
-----------	---	--	--	--	--

Designated States (Regional): AT BE CH DE ES FR GB GR IT LI LU NL SE

US 5217997	A	11	A61K-031/195	CIP of application US 90462638
------------	---	----	--------------	--------------------------------

Cont of application US 90513895

Abstract (Basic): EP 441119 A

For the treatment of hypertension, primary or secondary vasospasm, angina pectoris, cerebral ischaemia or preeclampsia (all claimed). Also claimed is the use of L-arginine to treat or prevent bronchial asthma. The compound is metabolised by endothelial cells to form nitric oxide, a vasodilator that works by increasing formation of c-GMP following direct interaction with the heme component of soluble guanylate cyclase (Ignarro et al, FASEB J., 3, 31-36 (1989)). Dose is oral or parenteral (e.g. i.p.), and is 1-1500 (10-400) mg/day. (14pp Dwg.No.0/3)

Title Terms: ARGININE; TREAT; HIGH; VASCULAR; RESISTANCE; DISORDER;

HYPERTENSIVE; BRONCHIAL; ASTHMA

Derwent Class: B05

International Patent Class (Main): A61K-031/195

International Patent Class (Additional): A61K-031/19

File Segment: CPI

1/5/1

DIALOG(R) File 351:Derwent WPI

(c) 2004 Thomson Derwent. All rts. reserv.

008735741

WPI Acc No: 1991-239757/ 199133

XRAM Acc No: C91-104187

**Use of L-arginine - to treat high vascular resistance disorders e.g.**

**hypertension and bronchial asthma**

Patent Assignee: LEVERE R D (LEVE-I)

Inventor: ABRAHAM N G; LEVERE R D; MARTASEK P; SCHWARTZMA M L; SCHWARTZMAN M L

Number of Countries: 015 Number of Patents: 004

Patent Family:

Patent No	Kind	Date	Applicat No	Kind	Date	Week
EP 441119	A	19910814	EP 91100168	A	19910107	199133 B
CA 2033766	A	19910710				199138
US 5217997	A	19930608	US 90462638	A	19900109	199324
			US 90513895	A	19900424	
			US 92873892	A	19920424	
EP 441119	A3	19921014	EP 91100168	A	19910107	199340

Priority Applications (No Type Date): US 90513895 A 19900424; US 90462638 A 19900109; US 92873892 A 19920424

Cited Patents: NoSR.Pub; 9.Jnl.Ref; FR 2507892; WO 8500517

Patent Details:

Patent No	Kind	Lan	Pg	Main IPC	Filing Notes
-----------	------	-----	----	----------	--------------

EP 441119	A				
-----------	---	--	--	--	--

Designated States (Regional): AT BE CH DE ES FR GB GR IT LI LU NL SE

US 5217997	A	11	A61K-031/195	CIP of application US 90462638
------------	---	----	--------------	--------------------------------

Cont of application US 90513895

Abstract (Basic): EP 441119 A

For the treatment of hypertension, primary or secondary vasospasm, angina pectoris, cerebral ischaemia or preeclampsia (all claimed). Also claimed is the use of L-arginine to treat or prevent bronchial asthma. The compound is metabolised by endothelial cells to form nitric oxide, a vasodilator that works by increasing formation of c-GMP following direct interaction with the heme component of soluble guanylate cyclase (Ignarro et al, FASEB J., 3, 31-36 (1989)). Dose is oral or parenteral (e.g. i.p.), and is 1-1500 (10-400) mg/day. (14pp Dwg.No.0/3)

Title Terms: ARGININE; TREAT; HIGH; VASCULAR; RESISTANCE; DISORDER; HYPERTENSIVE; BRONCHIAL; ASTHMA

Derwent Class: B05

International Patent Class (Main): A61K-031/195

International Patent Class (Additional): A61K-031/19

File Segment: CPI